We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

PD-1-PD-L1

PD-1/PD-L1 inhibitors are research compounds that block binding between an inhibitory T cell receptor and its ligand. Programmed cell death protein 1 (PD-1) was first identified in 1992 as a gene induced in cell lines undergoing programmed cell death. Its ligand, programmed death-ligand 1 (PD-L1), is a B7 family protein whose binding to PD-1 inhibits T cell proliferation and cytokine secretion. This checkpoint limits T cell activation and is studied in immune tolerance, tumor immunology and chronic infection. Small molecules such as BMS-202 bind PD-L1 and induce its dimerization, which hides the surface that engages PD-1. The category lists BMS-1166, BMS-202 and PD-1-IN-1 as small-molecule tools, alongside the anti-PD-L1 antibody avelumab as a reference reagent.

2 Items

  • PROTAC PD-1/PD-L1 degrader-1
    Cat. No.
    A24706
    CAS No.
    2447066-37-5

    PROTAC PD-1/PD-L1 degrader-1

    PROTAC PD-1/PD-L1 degrader-1 is a bifunctional degrader that targets the PD-1/PD-L1 immune checkpoint interaction by utilizing a Cereblon E3 ligase ligand. It demonstrates potent inhibitory activity with an IC50 of 39.2 nM, effectively restoring immune function in co-culture models involving liver cancer cells and CD3 T cells. Additionally, this compound reduces PD-L1 protein levels through a lysosome-dependent degradation pathway, making it a valuable tool for research in cancer immunotherapy and immune modulation.

    In stock View Details
    1 mg
    $200.00
    5 mg
    $510.00
    All 7 sizes
  • PROTAC PD-L1 degrader-2
    Cat. No.
    A35702
    CAS No.
    2995357-09-8

    PROTAC PD-L1 degrader-2

    PROTAC PD-L1 degrader-2 is a selective degrader targeting PD-L1. It demonstrates a potent inhibitory effect with an IC50 of 197.4 nM and a binding affinity characterized by a Kd of 301 nM. This compound facilitates the internalization and subsequent degradation of PD-L1 through both proteasomal and lysosomal pathways, thereby enhancing immune system activation. Its efficacy has been validated in MC38 C57BL/6 mouse models, underscoring its potential for antitumor applications.

    View Details

    Out of stock

    All 3 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...